METHODS AND MATERIALS FOR USING RUMINOCOCCUS GNAVUS OR CLOSTRIDIUM SPOROGENES TO TREAT GASTROINTESTINAL DISORDERS

• US 20170042860A1
• Filed: 08/12/2016
• Published: 02/16/2017
• Est. Priority Date: 08/12/2015
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Kashyap, Purna C., Fischbach, Michael
• Granted Patent: US 10,300,043 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

Claims

1. A method for treating a gastrointestinal disorder in a mammal, said method comprising administering a composition comprising at least one live bacterial organism having tryptophan decarboxylase activity to said mammal under conditions wherein gastrointestinal function of said mammal is improved.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said gastrointestinal disorder is irritable bowel syndrome.

4. The method of claim 1, wherein said at least one bacterial organism comprises endogenous tryptophan decarboxylase activity.

5. The method of claim 4, wherein said at least one bacterial organism comprising endogenous tryptophan decarboxylase activity is Ruminococcus gnavus or Clostridium sporogenes.

6. The method of claim 1, wherein said at least one bacterial organism comprises exogenous tryptophan decarboxylase activity.

7. The method of claim 6, wherein said at least one bacterial organism comprising exogenous tryptophan decarboxylase activity is Escherichia coli or Bacteroides thetaiotaomicron.

8. The method of claim 1, wherein said composition is a pill, tablet, or capsule.

9. The method of claim 8, wherein said composition is a pill, tablet, or capsule configured to deliver said at least one bacterial organism to the intestines of said mammal.

10. The method of claim 1, wherein said composition comprises no more than one bacterial species, and wherein said bacterial organism is a member of said one bacterial species.

11. The method of claim 10, wherein said bacterial species is Ruminococcus gnavus or Clostridium sporogenes.

12. The method of claim 1, wherein said method comprises identifying said mammal as having said gastrointestinal disorder prior to said administration.

13. A composition comprising at least one bacterial organism comprising exogenous tryptophan decarboxylase activity.

14. The composition of claim 13, wherein said at least one bacterial organism is Escherichia coli or Bacteroides thetaiotaomicron.

15. The composition of claim 13, wherein said composition is a pill, tablet, or capsule.

16. The composition of claim 13, wherein said composition comprises no more than one bacterial species, and wherein said bacterial organism is a member of said one bacterial species.

17. The composition of claim 13, wherein said composition comprises tryptophan.

18. A composition comprising tryptophan and at least one bacterial organism comprising tryptophan decarboxylase activity.